Celcuity (CELC) Stock Price

Celcuity Price

🇺🇸NASDAQ·CLOSED
87.44USD
Market closed
Today +/-
Today %

Celcuity (CELC) Stock | ISIN US15102K1007 | WKN A2JAAX. The current Celcuity stock price is 87.44 USD (2026). Revenue is 44.91 M USD. Net income is -164.18 M USD. The P/E ratio is -21.01. Market capitalization is 3.45 B USD. Celcuity operates in the Health sector.

Celcuity stock price

Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Celcuity over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Celcuity stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Celcuity's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Celcuity Stock Price History
DateCelcuity Price
Access this data via the Eulerpool API

Celcuity Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2015
0 USD
-2.26 M USD
-2.26 M USD
Jan 1, 2016
0 USD
-3.33 M USD
-3.31 M USD
Jan 1, 2017
0 USD
-5.95 M USD
-6.25 M USD
Jan 1, 2018
0 USD
-7.93 M USD
-7.48 M USD
Jan 1, 2019
0 USD
-7.81 M USD
-7.36 M USD
Jan 1, 2020
0 USD
-9.56 M USD
-9.47 M USD
Jan 1, 2021
0 USD
-28.36 M USD
-29.61 M USD
Jan 1, 2022
0 USD
-39.39 M USD
-40.37 M USD
Jan 1, 2023
0 USD
-66.23 M USD
-63.78 M USD
Jan 1, 2024
0 USD
-113.27 M USD
-111.78 M USD
Invalid Date
0 USD
-173.26 M USD
-150.43 M USD
Invalid Date
44.91 M USD
-198.98 M USD
-164.18 M USD
Invalid Date
362.38 M USD
26.91 M USD
-47.37 M USD
Invalid Date
718.6 M USD
299.28 M USD
182.48 M USD
Invalid Date
1.07 B USD
572.4 M USD
371.8 M USD

Celcuity Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 11, 2026, 6:18 AM
 
REVENUE (M USD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M USD)
NET INCOME (M USD)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Celcuity generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Celcuity retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Celcuity's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Celcuity has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Celcuity's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Celcuity stock margins

The Celcuity margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Celcuity. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Celcuity.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2015
0 %
- %
- %
Jan 1, 2016
0 %
- %
- %
Jan 1, 2017
0 %
- %
- %
Jan 1, 2018
0 %
- %
- %
Jan 1, 2019
0 %
- %
- %
Jan 1, 2020
0 %
- %
- %
Jan 1, 2021
0 %
- %
- %
Jan 1, 2022
0 %
- %
- %
Jan 1, 2023
0 %
- %
- %
Jan 1, 2024
0 %
- %
- %
Invalid Date
0 %
- %
- %
Invalid Date
0 %
-443.03 %
-365.54 %
Invalid Date
0 %
7.43 %
-13.07 %

Celcuity Stock Revenue, EBIT, Earnings per Share

The Celcuity earnings per share therefore indicates how much revenue Celcuity has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2015
0 USD
-0.24 USD
-0.24 USD
Jan 1, 2016
0 USD
-0.36 USD
-0.35 USD
Jan 1, 2017
0 USD
-0.8 USD
-0.84 USD
Jan 1, 2018
0 USD
-0.78 USD
-0.74 USD
Jan 1, 2019
0 USD
-0.76 USD
-0.72 USD
Jan 1, 2020
0 USD
-0.93 USD
-0.92 USD
Jan 1, 2021
0 USD
-2.12 USD
-2.21 USD
Jan 1, 2022
0 USD
-2.55 USD
-2.62 USD
Jan 1, 2023
0 USD
-2.8 USD
-2.69 USD
Jan 1, 2024
0 USD
-2.87 USD
-2.83 USD
Invalid Date
0 USD
-4.39 USD
-3.81 USD
Invalid Date
1.14 USD
-5.04 USD
-4.16 USD
Invalid Date
9.19 USD
0.68 USD
-1.2 USD

Celcuity business model & stock analysis

Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide.

Celcuity SWOT Analysis

Strengths

Celcuity Inc possesses several strengths that contribute to its competitive advantage in the market:

  • Cutting-edge technology and innovative solutions
  • Strong intellectual property portfolio
  • Highly skilled and experienced research and development team
  • Strong relationships with key industry partners
  • Solid financial position and strong revenue growth

Weaknesses

Despite its strengths, Celcuity Inc also has certain weaknesses that can impact its performance:

  • Relatively small size compared to established competitors
  • Limited brand recognition in the market
  • Dependency on a few key customers
  • Limited marketing and distribution capabilities
  • Risk of potential regulatory challenges

Opportunities

Celcuity Inc can capitalize on the following opportunities to further expand and develop its business:

  • Growing demand for personalized medicine and targeted therapies
  • Increase in healthcare spending and focus on precision oncology
  • Expansion into new geographic markets
  • Potential collaborations and partnerships with pharmaceutical companies
  • Advancements in technology and data analytics

Threats

Celcuity Inc faces the following threats that may hinder its growth and success:

  • Intense competition from established players in the industry
  • Fast-paced technological advancements and potential disruption
  • Stringent regulations and compliance requirements
  • Economic fluctuations and market uncertainties
  • Potential intellectual property disputes and legal challenges

Celcuity Eulerpool Fair Value

Celcuity historical P/E ratio, EBIT multiple, and P/S ratio

Celcuity annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Celcuity shares outstanding

The number of shares was Celcuity in 2025 — This indicates how many shares 39.449 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2015
9.37 M base_Shares
Jan 1, 2016
9.37 M base_Shares
Jan 1, 2017
7.46 M base_Shares
Jan 1, 2018
10.12 M base_Shares
Jan 1, 2019
10.23 M base_Shares
Jan 1, 2020
10.27 M base_Shares
Jan 1, 2021
13.38 M base_Shares
Jan 1, 2022
15.42 M base_Shares
Jan 1, 2023
23.68 M base_Shares
Jan 1, 2024
39.45 M base_Shares
Invalid Date
39.45 M base_Shares
Invalid Date
39.45 M base_Shares
Invalid Date
39.45 M base_Shares
Price targets and forecasts for Celcuity are not yet available.

Celcuity Earnings Estimates

Celcuity Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/18/2026-1.07USD0USD2026 Q1
5/14/2026-1.07USD0USD2026 Q1
5/12/2026-1.07USD0USD2026 Q1
3/25/2026-1.06USD0USD2025 Q4
3/19/2026-1.06USD0USD2025 Q4
11/14/2024-0.67USD0USD2024 Q3
11/11/2024-0.67USD0USD2024 Q3
5/13/2024-0.81USD0USD2024 Q1
3/21/2024-0.82USD0USD2023 Q4
11/8/2023-0.41USD0USD2023 Q3

EESG©

Eulerpool ESG Scorecard© for the Celcuity stock

51/100
54
Environment
59
Social
40
Governance
E

Environment

20
Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Celcuity shareholder structure

% Name
20.06568%
Baker Bros. Advisors LP
Baker Bros. Advisors LP
8.01077%
Perceptive Advisors LLC
Perceptive Advisors LLC
7.91136%
Sullivan (Brian F)
Sullivan (Brian F)
7.88633%
Avoro Capital Advisors LLC
Avoro Capital Advisors LLC
7.37796%
New Enterprise Associates (NEA)
New Enterprise Associates (NEA)
5.76979%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
5.68708%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
4.58374%
Soleus Capital Management, L.P.
Soleus Capital Management, L.P.
4.34481%
Deerfield Management Company, L.P.
Deerfield Management Company, L.P.
4.15136%
State Street Investment Management (US)
State Street Investment Management (US)
...

Celcuity Executives and Management Board

BS

Mr. Brian Sullivan

(63)

Chairman of the Board, Chief Executive Officer, Co-Founder · since 2012

Compensation6.59 M USD
LL

Dr. Lance Laing

(63)

Co-Founder, Chief Science Officer, Vice President, Secretary, Director · since 2012

Compensation1.7 M USD
VH

Ms. Vicky Hahne

(58)

Chief Financial Officer

Compensation1.35 M USD
RB

Dr. Richard Buller

(75)

Independent Director

Compensation107,500 USD
DD

Mr. David Dalvey

(66)

Independent Director

Compensation107,500 USD

Celcuity Supply Chain

Frequently asked questions about Celcuity

Celcuity Inc, a targeted diagnostics company, operates on a unique business model focusing on developing and commercializing novel companion diagnostic tests. By analyzing a patient's living cancer cells used in diagnostic testing, Celcuity gathers crucial data to identify abnormal signaling pathways that can guide physicians in selecting the most effective treatment. Leveraging its proprietary CELsignia platform, Celcuity aims to improve patient outcomes by enabling the identification of patients who are likely to respond favorably to specific targeted therapies. Through its innovative approach, Celcuity strives to revolutionize personalized medicine in the field of cancer diagnostics.

All fundamentals and in-depth analysis of Celcuity

Our stock analysis for Celcuity Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celcuity Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.